Q4 2024 EPS Estimates for Nicox S.A. Decreased by HC Wainwright (OTCMKTS:NICXF)

Nicox S.A. (OTCMKTS:NICXF) – Equities researchers at HC Wainwright reduced their Q4 2024 earnings per share (EPS) estimates for Nicox in a note issued to investors on Tuesday, April 23rd. HC Wainwright analyst R. Selvaraju now anticipates that the company will earn ($0.06) per share for the quarter, down from their previous estimate of ($0.05). The consensus estimate for Nicox’s current full-year earnings is ($0.30) per share. HC Wainwright also issued estimates for Nicox’s Q1 2024 earnings at ($0.03) EPS, Q2 2024 earnings at ($0.09) EPS, Q3 2024 earnings at ($0.07) EPS and FY2024 earnings at ($0.26) EPS.

Nicox Stock Performance

Shares of NICXF opened at $0.44 on Thursday. The business’s fifty day moving average is $0.44 and its 200 day moving average is $0.52. Nicox has a 12-month low of $0.44 and a 12-month high of $0.44.

Nicox Company Profile

Nicox SA operates as an ophthalmology company in France and internationally. The company develops solutions to maintain vision and improve ocular health. Its lead product candidate is NCX 470, a novel nitric oxide-donating bimatoprost eye drop for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in Phase 3 clinical trial.